Antipsychotic maintenance treatment: time to rethink
Open accessAbstract
Joanna Moncrieff looks at the lack of long-term evidence for antipsychotic medication and considers what is needed to ensure we have the knowledge to maximize benefits and minimize harms.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Upon removal of D2 blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [7]
The Evidence for Maintenance Therapy section says antipsychotic withdrawal may make relapse more likely in people with schizophrenia. It does not describe persistently increased presynaptic DSC or an interaction with elevated postsynaptic sensitivity; searches for those mechanisms found no supporting passage. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · see citing works
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194 · see citing works
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · see citing works
Size of burden of schizophrenia and psychotic disorders
Wulf Rössler, A., Salize, H. J., van Os, J., & Riecher‐Rössler, A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.009 · Cited by 746 · see citing works
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., BALL, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · see citing works
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · see citing works
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.19 · Cited by 567 · see citing works
Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., & Borgwardt, S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.001 · Cited by 512 · see citing works
The Final 10-Year Follow-Up Results From the BARI Randomized Trial
(2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.048 · Cited by 447 · see citing works
Dorph‐Petersen, K., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300710 · Cited by 438 · see citing works
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434 · see citing works
Schizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395 · see citing works
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392 · see citing works
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f53132 · Cited by 367 · see citing works
The Myth of Schizophrenia as a Progressive Brain Disease
Zipursky, R. B., Reilly, T. J., & Murray, R. M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs135 · Cited by 336 · see citing works
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320 · see citing works
A systematic review of the effects of antipsychotic drugs on brain volume
Moncrieff, J., & Leo, J. (2010) · Psychological Medicine · doi:10.1017/s0033291709992297 · Cited by 309 · see citing works
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mci.0b013e328303e7a6 · Cited by 291 · see citing works
Wiersma, D., WANDERLING, J. A., Dragomirecká, E., GANEV, K., Harrison, G. L., der Heiden, W. A., Nienhuis, F. J., & Walsh, D. (2000) · Psychological Medicine · doi:10.1017/s0033291799002627 · Cited by 251 · see citing works
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246 · cited 1× · see citing works
“Relapses cluster around the point of withdrawal in most studies, for example, and one meta-analysis found that gradual withdrawal reduced the risk of relapse [15], although a recent meta-analysis did not replicate this finding [11].”
ResultWunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234 · see citing works
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231 · see citing works
Harrow, M., & Jobe, T. H. (2007) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000253783.32338.6e · Cited by 218 · see citing works
Lieberman, J. A., Koreen, A., Chakos, M., Sheitman, B., Woerner, M. G., Alvir, J. M. J., & Bilder, R. M. (1996) · PubMed · Cited by 211 · see citing works
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 194 · see citing works
Harrow, M., Jobe, T. H., & Faull, R. N. (2012) · Psychological Medicine · doi:10.1017/s0033291712000220 · Cited by 192 · see citing works
Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications
Woods, S. W., Morgenstern, H., Saksa, J. R., Walsh, B. C., Sullivan, M. C., Money, R. W., Hawkins, K. A., Gueorguieva, R. V., & Glazer, W. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03890yel · Cited by 186 · see citing works
Maintenance antipsychotic therapy: is the cure worse than the disease?
Gárdos, G., & Cole, J. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.1.32 · Cited by 178 · see citing works
The subjective experience of taking antipsychotic medication: a content analysis of Internet data
Moncrieff, J., Cohen, D., & Mason, J. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01356.x · Cited by 154 · see citing works
A controlled evaluation of lithium prophylaxis in affective disorders
Cundall, R., Brooks, P. W., & Murray, L. G. (1972) · Psychological Medicine · doi:10.1017/s0033291700042616 · Cited by 147 · see citing works
Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children
Pringsheim, T. M., Lam, D., Ching, H., & Patten, S. B. (2011) · Drug Safety · doi:10.2165/11592020-000000000-00000 · Cited by 135 · see citing works
Albaugh, V. L., Singareddy, R. K., Mauger, D., & Lynch, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022662 · Cited by 119 · see citing works
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.030 · Cited by 110 · see citing works
Methodological Issues in Current Antipsychotic Drug Trials
Leucht, S., Heres, S., Hamann, J., & Kane, J. M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm159 · Cited by 96 · see citing works
Whitaker, R. (2010) · Cited by 90 · see citing works
Sex Differences in the Subjective Tolerability of Antipsychotic Drugs
Barbui, C., Nos??, M., Bindman, J. P., Schene, A. H., Becker, T. M., Mazzi, M. A., Kikkert, M., Camara, J., Born, A., & Tansella, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185423.15891.02 · Cited by 86 · see citing works
Clinical Psychopharmacology in Its 20th Year
Crane, G. E. (1973) · Science · doi:10.1126/science.181.4095.124 · Cited by 80 · see citing works
Murray‐Thomas, T., Jones, M., Patel, D., Brunner, E., Shatapathy, C. C., Motsko, S. P., & van Staa, T. P. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/247486 · Cited by 71 · see citing works
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1990) · Psychological Medicine · doi:10.1017/s0033291700036527 · Cited by 61 · see citing works
Clozapine withdrawal rebound psychosis.
Borison, R. L., Diamond, B. I., Sinha, D., Gupta, R. P., & Ajiboye, P. O. (1988) · PubMed · Cited by 56 · see citing works
Neurocognition and recovery in first episode psychosis
Faber, G., Smid, H. G. O. M., Gool, A. R. V., Wunderink, L., Wiersma, D., & van den Bosch, R. J. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.11.010 · Cited by 46 · see citing works
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341178 · Cited by 45 · see citing works
Ryu, S., Yoo, J. H., Kim, J. H., Choi, J. S., Baek, J. H., Ha, K., Kwon, J. S., & Hong, K. S. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000250 · Cited by 42 · see citing works
Kim, J., MacMaster, E. R., & Schwartz, T. L. (2014) · Drugs in Context · doi:10.7573/dic.212259 · Cited by 32 · see citing works
Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia.
Diamond, B. I., & Borison, R. L. (1986) · PubMed · Cited by 19 · see citing works
Moncrieff, J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.085795 · Cited by 16 · see citing works
Rationale and Parameters for Medication-Free Research in Psychosis
McGlashan, T. H. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj045 · Cited by 10 · see citing works
Chan, H., Chen, C. H., Chen, J. J., Sun, H., Chiu, H.-J., & Chang, C. J. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92037-2 · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [42]Chan HY, Chen CH, Chen JJ, Sun HJ, Chiu HJ, Chang CJ. A comparison of risperidone and olanzapine for schizophrenia patients intolerance of neuroleptic-induced extra-pyramidal syndromes. Journal of the European College of Neuropsychopharmacology 2003; 13: S316.
Cited by
Sorted by citations
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324 · see citing works
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244 · see citing works
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
GOFF, D. C., Falkai, P., Fleischhacker, W. W., Girgis, R. R., Kahn, R. S., Uchida, H., Zhao, J., & Lieberman, J. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091016 · Cited by 194 · see citing works
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Metacognitive Reflection and Insight Therapy: A Recovery-Oriented Treatment Approach for Psychosis
Lysaker, P. H., Gagen, E. C., Klion, R. E., Zalzala, A. B., Vohs, J. L., Faith, L. A., Leonhardt, B. L., Hamm, J. A., & Hasson‐Ohayon, I. (2020) · Psychology Research and Behavior Management · doi:10.2147/prbm.s198628 · Cited by 104 · see citing works
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73 · see citing works
Ilyas, A., Chesney, E., & Patel, R. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.117.203240 · Cited by 71 · see citing works
Bowtell, M., Ratheesh, A., McGorry, P., Killackey, E., & O'Donoghue, B. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.010 · Cited by 62 · see citing works
Bogers, J. P. A. M., Hambarian, G., Schmidt, N. W., Vermeulen, J. M., & de Haan, L. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac138 · Cited by 57 · see citing works
Cooper, R. E., Laxhman, N., Crellin, N. E., Moncrieff, J., & Priebe, S. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.020 · Cited by 56 · see citing works
Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P., & Correll, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 53 · see citing works
Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
Cooper, R. E., Hanratty, É., Morant, N., & Moncrieff, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218711 · Cited by 49 · see citing works
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03822-5 · Cited by 44 · see citing works
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain.
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz-Marsá, M., García-Portilla, M., Gutiérrez-Rojas, L., Olivares, J. M., Rico-Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.03.006 · Cited by 25 · see citing works
Zaher, F., Diallo, M., Achim, A. M., Joober, R., Roy, M., Demers, M., Subramanian, P., Lavigne, K. M., Lepage, M., Gonzalez, D., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.02.036 · Cited by 30 · see citing works
Collaborative care approaches for people with severe mental illness
Reilly, S., Hobson-Merrett, C., Gibbons, B., Jones, B., Richards, D., Plappert, H., Gibson, J., Green, M., Gask, L., Huxley, P. J., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009531.pub3 · Cited by 29 · see citing works
Fountoulakis, K., Moeller, H., Kasper, S., Tamminga, C., Yamawaki, S., Kahn, R., Tandon, R., Correll, C., & Javed, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920001546 · Cited by 25 · see citing works
Antipsychotic treatment: experiences of fully recovered service users
Bjørnestad, J. R., Davidson, L., Joa, I., Larsen, T. K., Hegelstad, W. T. V., Langeveld, J., Veseth, M., Melle, I. S., Johannessen, J. O., & Brønnick, K. (2017) · Journal of Mental Health · doi:10.1080/09638237.2017.1294735 · Cited by 28 · see citing works
The experiences of 585 people when they tried to withdraw from antipsychotic drugs
Read, J. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100421 · Cited by 24 · see citing works
Horowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 22 · see citing works
Gómez‐Revuelta, M., Pelayo‐Terán, J. M., Juncal‐Ruíz, M., de la Foz, V. O., Vázquez-Bourgón, J., González-Pinto, A. M., & Crespo‐Facorro, B. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy082 · Cited by 20 · see citing works
Cooper, R. E., Mason, J., Calton, T., Richardson, J. M., & Moncrieff, J. (2021) · Psychosis · doi:10.1080/17522439.2021.1930119 · Cited by 26 · see citing works
La, M. K., Thompson Bastin, M. L., Gisewhite, J. T., Johnson, C. A., & Flannery, A. H. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.07.046 · Cited by 17 · see citing works
The Effects of Antipsychotic Drugs and Non-Pharmacological Therapies on Schizophrenia
Nasim, R., Nawaz, S., & Nasim, T. (2025) · Targets · doi:10.3390/targets3010010 · Cited by 19 · see citing works
Antipsychotic Discontinuation through the Lens of Epistemic Injustice
Speyer, H., Eplov, L. F., & Roe, D. (2024) · Community Mental Health Journal · doi:10.1007/s10597-024-01274-7 · Cited by 16 · see citing works
Conceptualization and Study of Antipsychotic Medication Use: From Adherence to Patterns of Use
Roe, D., Jones, N., Hasson‐Ohayon, I., & Zisman‐Ilani, Y. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202100006 · Cited by 15 · see citing works
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz-Marsá, M., García-Portilla, M., Gutiérrez-Rojas, L., Olivares, J., Rico-Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.03.004 · Cited by 28 · see citing works
The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia
Davidson, M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.3/mdavidson · Cited by 14 · see citing works
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13 · see citing works
“91 These theories have been hypothesized because of antipsychotic withdrawal, which would result in rebound psychosis, 92 but this theory has not been validated by either clinical research of abrupt versus progressive treatment discontinuation, 88 nor neurobiological research on dopamine receptor…”
BackgroundKoops, S., Allott, K., de Haan, L., Chen, E. Y. H., Hui, C. L. M., Killackey, E. J., Long, M., Moncrieff, J., Sommer, I. E., Stürup, A. E., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad112 · Cited by 13 · see citing works
Schlier, B., Buck, L., Müller, R., Lincoln, T. M., Bott, A., & Pillny, M. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102291 · Cited by 14 · see citing works
Asher, M., Roe, D., & Hasson‐Ohayon, I. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1133140 · Cited by 12 · see citing works
Haloperidol discontinuation for people with schizophrenia
Essali, A., Turkmani, K., Aboudamaah, S., AbouDamaah, A., Aldeen, M. R. D., Marwa, M. E., & Almounayer, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011408.pub2 · Cited by 12 · see citing works
Cooper, R. E., Grünwald, L. M., & Horowitz, M. A. (2020) · Psychosis · doi:10.1080/17522439.2020.1722734 · Cited by 12 · see citing works
Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia.
Rubio, J., Malhotra, A., & Kane, J. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113099 · Cited by 13 · see citing works
Predictors of successful discontinuation of antipsychotics and antidepressants
Lincoln, T. M., Sommer, D., Quazzola, M., Witzgall, T., & Schlier, B. (2021) · Psychological Medicine · doi:10.1017/s0033291721005146 · Cited by 12 · see citing works
Recovery without normalisation: It's not necessary to be normal, not even in psychiatry
Chappell, Z., & Jeppsson, S. M. I. (2023) · Clinical Ethics · doi:10.1177/14777509231165880 · Cited by 11 · see citing works
Chatterjee, I., & Chatterjee, S. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.03.008 · Cited by 11 · see citing works
Son, J. M.-V., Juncal‐Ruíz, M., de la Foz, V. O., Vázquez-Bourgón, J., Setién‐Suero, E., Tordesillas‐Gutiérrez, D., Gómez‐Revuelta, M., Ayesa‐Arriola, R., & Crespo‐Facorro, B. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.04.011 · Cited by 10 · see citing works
Otręba, M., Beberok, A., Wrześniok, D. M., & Buszman, E. (2018) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-018-0206-4 · Cited by 10 · see citing works
Read, J. (2022) · Journal of Mental Health · doi:10.1080/09638237.2022.2069708 · Cited by 7 · see citing works
King, S. R., Allan, M., & Lindsey, L. (2022) · Psychosis · doi:10.1080/17522439.2022.2141841 · Cited by 8 · see citing works
Radical psychotic doubt and epistemology
Jeppsson, S. M. I. (2022) · Philosophical Psychology · doi:10.1080/09515089.2022.2147815 · Cited by 7 · see citing works
Emsley, R. A., Fleischhacker, W. W., Galderisi, S., Halpern, L., McEvoy, J. P., & Schooler, N. R. (2016) · BMJ · doi:10.1136/bmj.i4728 · Cited by 7 · see citing works
Ringen, P. A., Reponen, E. J., Vedal, T. S. J., Andreassen, O. A., Steen, N. E., & Melle, I. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00649 · Cited by 7 · see citing works
Cipolla, S., Catapano, P., D’Amico, D., Monda, R., Sallusto, N. P., Perris, F., Santis, V. D., Catapano, F., Luciano, M., & Fiorillo, A. (2024) · Brain Sciences · doi:10.3390/brainsci14050433 · Cited by 8 · see citing works
The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review
Mercurio, M., Spina, G., Galasso, O., Gasparini, G., Segura‐Garcìa, C., Fazio, P. D., & de Filippis, R. (2024) · Diagnostics · doi:10.3390/diagnostics14232745 · Cited by 5 · see citing works
An Alternative Approach to Drug Treatment in Psychiatry
Moncrieff, J. (2018) · Springer eBooks · doi:10.1007/978-3-030-02732-2_4 · Cited by 5 · see citing works
Systematic violations of patients’ rights and safety: Forced medication of a cohort of 30 patients
Gøtzsche, P. C., & Sørensen, A. (2020) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2020.085 · Cited by 5 · see citing works
Liu, C.-I., Liu, C., Chiu, H.-H., Chuang, C.-C., Hwang, T., Hsieh, M. H., Chien, Y., Lin, Y., Yen, K., & Liu, C. (2024) · Psychological Medicine · doi:10.1017/s0033291724002356 · Cited by 4 · see citing works
Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how?
Emsley, R. A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.10.047 · Cited by 4 · see citing works
A realidade social brasileira e o retrocesso na Saúde Mental
Leal, E. M., & Ferrari, I. F. (2019) · Revista Latinoamericana de Psicopatologia Fundamental · doi:10.1590/1415-4714.2019v22n3p421.1 · Cited by 4 · see citing works
Maintenance antipsychotic trials and the effect of withdrawal
Munkholm, K., Horowitz, M. A., & Moncrieff, J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01467-2 · Cited by 4 · see citing works
Fountoulakis, K. Ν. (2021) · Springer eBooks · doi:10.1007/978-3-030-86541-2_25 · Cited by 3 · see citing works
Marić, N. P., Petrović, S. A., Russo, M., Jerotić, S., Ristić, I., Savić, B., Pemovska, T., Milutinović, M., Ribić, E., Markovska-Simoska, S., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.796719 · Cited by 3 · see citing works
Read, J. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12551 · Cited by 3 · see citing works
Tasch, G., & Gøtzsche, P. C. (2023) · Psychosis · doi:10.1080/17522439.2023.2183428 · Cited by 2 · see citing works
Fountoulakis, K. Ν., Panagiotidis, P., & Nimatoudis, I. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2712 · Cited by 2 · see citing works
Guest editorial: Special issue on maintenance treatment in schizophrenia.
Emsley, R. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.029 · Cited by 2 · see citing works
Schneidman, A., Roe, D., Zisman‐Ilani, Y., & Shpigelman, C. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251326293 · Cited by 1 · see citing works
Hüppi, R. M., Bautista, L., Cecere, G., Omlor, W., Just, S. A., Koops, S., Hussain, M., Tedeschi, E., Benke-Bruderer, S., Bora, E., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-114585 · Cited by 1 · see citing works
Research on maintenance treatment to prevent relapse of psychotic disorders
Hui, C. L. M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114928 · Cited by 1 · see citing works
Antipsychotic Drugs: Do They Define Schizophrenia or Do They Blunt All Emotions?
Belmaker, R. H., & Lichtenberg, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-40371-2_6 · Cited by 1 · see citing works
Schizophrenia and Related Psychoses
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg001.pub2 · Cited by 1 · see citing works
Hüppi, R. M., Bautista, L., Cecere, G., Just, S. A., Koops, S., Hussain, M., Tedeschi, E., Benke-Bruderer, S., Bora, E., Lyne, J., et al. (2025) · medRxiv · doi:10.1101/2025.11.14.25339774 · Cited by 1 · see citing works
D’Avanzo, B., & Parabiaghi, A. (2016) · RIVISTA SPERIMENTALE DI FRENIATRIA · doi:10.3280/rsf2016-002002
Sierra, M. D. C. (2017) · Clínica Contemporánea · doi:10.5093/cc2017a23
Antipsychotic use in older adults
Pathak, S., & Duff, E. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000532766.14251.c7
Percepção da Equipe de Saúde da Família sobre o cuidado a usuários de drogas
Lira, L. S. S. P., Andrade, L. M., Peixoto, L. C. P., Malhado, S. D. C. B., & Sena, E. L. D. S. (2020) · Saúde em Debate · doi:10.1590/0103-1104202012507
Perception of the Family Health Team on the care of drug user
Lira, L. S. S. P., Andrade, L. M., Peixoto, L. C. P., Malhado, S. D. C. B., & Sena, E. L. D. S. (2020) · Saúde em Debate · doi:10.1590/0103-1104202012507i
Inclusão de pessoas com transtorno mental no trabalho formal: percepções dos familiares
Lamb, P. P., Sarmento, W. M., Machado, J., Rainone, F. N., Ferreira, C. V. P., & Estivalet, A. G. (2021) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/psicologia/transtorno-mental
From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era
Fountoulakis, K. Ν. (2021) · Springer eBooks · doi:10.1007/978-3-030-86541-2_11
Neuroleptics Do Much More Harm Than Good and Should Not Be Used
Gøtzsche, P. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-27003-1_4
EL TRATAMIENTO DE ENFERMEDADES MENTALES GRAVES DESDE LA INVESTIGACIÓN DE PROCESOS
de Psicología, U. A. D. M. F., Alonso‐Vega, J., de Prado‐Gordillo, M. N., Pereira, G.-L., & Parga, M. X. F. (2019) · CONDUCTUAL · doi:10.59792/yvvn1823
Matete, R. P., & Rathobei, L. M. (2023) · New Voices in Psychology · doi:10.25159/2958-3918/14085
Insights in social psychiatry and psychiatric rehabilitation: 2022
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4568-3
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19366114
Moncrieff, J., Long, M., Priebe, S., Akther-Robertson, J., Barnes, T. R. E., Bray, G., Cooper, R. E., Crellin, N. E., Darton, K., Freemantle, N., et al. (2025) · Programme Grants for Applied Research · doi:10.3310/gjjm0506
Berna, F., Horowitz, M., Javelot, H., Meyer, N., & Foucher, J. R. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-117593
- Authors
- Moncrieff, J.
- Affiliations
- University College London (GB)
- Corresponding author
- Moncrieff, Joanna
- ORCID
- Moncrieff, Joanna
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-08-04
- Volume
- 12
- Issue
- 8
- Pages
- e1001861
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC4524699
- OpenAlex
- W1079720927
- Cited by
- 80
- References
- 50
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 10 · 2022: 11 · 2021: 10 · 2020: 7 · 2019: 8 · 2018: 7 · 2017: 7 · 2016: 3
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- antipsychotic drugs, maintenance therapy, schizophrenia, drug-related harm, benefit-harm balance
- MeSH terms
- Drug Administration Schedule, Humans, Recurrence, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Disease Progression, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
